SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
NCT07141329
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Focal Onset Seizures
Interventions
DRUG:
SPN-817
Sponsor
Supernus Pharmaceuticals, Inc.